Table 10 Selected phase 1/2 trials in NTRK rearranged NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Objective response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|
Navigate | NCT02568267 | Larotrectinib | 75 | 28.3 | 44.4 |
Pooled analysis of STARTRK-1, STARTRK-2, ALKA-372 | NA | Entrectinib | 70 | 14.9 | NR |